Low Testosterone Levels Tied to More Severe COVID in Men
MONDAY, Sept. 5, 2022 -- Men with low testosterone levels may be more likely to have more severe illness when infected with COVID-19, according to a new study.
Treating men who have low testosterone with hormone therapy may reduce their risk of... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - September 5, 2022 Category: General Medicine Source Type: news
Low Testosterone Linked to Hospitalization for COVID
(MedPage Today) -- Normal testosterone levels in men might be protective against severe COVID-19, a retrospective cohort study suggested.
Among 723 men with a mean age of 55, those who had hypogonadism had a higher risk of hospitalization for... (Source: MedPage Today Endocrinology)
Source: MedPage Today Endocrinology - September 2, 2022 Category: Endocrinology Source Type: news
New Oral Testosterone OK'd; Jarlsberg for Osteoporosis; Menopausal Women Lighting Up
(MedPage Today) -- The FDA approved a new oral testosterone undecanoate (Kyzatrex), primarily absorbed via the lymphatic system, for men with hypogonadism, Marius Pharmaceuticals announced.
The Women's Preventive Services Initiative released new... (Source: MedPage Today Endocrinology)
Source: MedPage Today Endocrinology - August 3, 2022 Category: Endocrinology Source Type: news
FDA Approves Kyzatrex (testosterone undecanoate) for the Treatment of Male Hypogonadism
RALEIGH, N.C., Aug. 02, 2022 (GLOBE NEWSWIRE) -- Marius Pharmaceuticals, a patient-centric healthcare company, today announced the approval of Kyzatrex (testosterone undecanoate) by the U.S. Food and Drug Administration (FDA). Kyzatrex is an oral... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - August 2, 2022 Category: Drugs & Pharmacology Source Type: news
Raleigh pharma earns FDA approval for low testosterone drug
A Raleigh drugmaker developing therapies for testosterone deficiency has secured its first approval from the FDA. Next up, international markets. (Source: bizjournals.com Health Care:Physician Practices headlines)
Source: bizjournals.com Health Care:Physician Practices headlines - August 2, 2022 Category: American Health Authors: Zac Ezzone Source Type: news
Bayer to sell men's health product Nebido ™ to Grünenthal
Bayer and Grünenthal have entered into a definitive agreement regarding the sale of Bayer's men's health product Nebido™ (testosterone undecanoate), for a purchase price totaling up to 500 million Euro.
Nebido for the treatment of male hypogonadism (testosterone deficiency) is available in over 80 countries since 2004. In 2021, the product contributed sales of 117 million Euro to Bayer's overall sales of more than 44 billion Euro. (Source: World Pharma News)
Source: World Pharma News - July 18, 2022 Category: Pharmaceuticals Tags: Featured Bayer Business and Industry Source Type: news
When to Treat Low Testosterone in Diabetes and Obesity When to Treat Low Testosterone in Diabetes and Obesity
Obesity or diabetes alone does not constitute a reason for screening for testosterone deficiency. But clinicians should screen for the symptoms of this deficiency.Medscape Medical News (Source: Medscape Diabetes Headlines)
Source: Medscape Diabetes Headlines - July 15, 2022 Category: Endocrinology Tags: Diabetes & Endocrinology News Source Type: news
Mayo Clinic Minute: How low testosterone can affect men's health
Millions of men live with a testosterone deficiency. If left unchecked, this treatable condition may contribute to serious health problems like osteoporosis and lowered red blood cell production. During National Men's Health Week — June 13–19 — Dr. Gregory Broderick, a Mayo Clinic urologist, encourages men with symptoms of low testosterone to speak with their health care team. Watch: The Mayo Clinic Minute https://www.youtube.com/watch?v=zLjkjFfFC8Y Journalists: Broadcast-quality video pkg (1:07) is in the downloads at the end… (Source: News from Mayo Clinic)
Source: News from Mayo Clinic - June 16, 2022 Category: Databases & Libraries Source Type: news
No Early Cardiovascular Risks With Testosterone Treatment
(MedPage Today) -- Testosterone treatment for hypogonadism did not increase short- or medium-term risks for cardiovascular events, according to a systematic review and meta-analysis.
Cardiovascular risks were similar between men in the testosterone... (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - June 14, 2022 Category: Cardiology Source Type: news
Male Contraceptive Pill Appears Feasible in Very Early Trials Male Contraceptive Pill Appears Feasible in Very Early Trials
By lowering testosterone levels without untoward hypogonadism, early data show that once-daily contraceptive pills for men could be feasible.Medscape Medical News (Source: Medscape Diabetes Headlines)
Source: Medscape Diabetes Headlines - June 11, 2022 Category: Endocrinology Tags: Diabetes & Endocrinology News Source Type: news
Testosterone Therapy for Hypogonadism Not Tied to Increased CV Risk
FRIDAY, June 10, 2022 -- For men with hypogonadism, testosterone therapy does not appear to increase short- to medium-term cardiovascular risk, according to a review published in the June issue of The Lancet Healthy Longevity.
Jemma Hudson, from the... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - June 10, 2022 Category: Pharmaceuticals Source Type: news
Jury Still Out on Cardiovascular Safety of Testosterone Jury Still Out on Cardiovascular Safety of Testosterone
A meta-analysis may provide some reassurance of the short-term cardiovascular safety of testosterone therapy for male hypogonadism until definitive 5-year TRAVERSE trial findings are available, expected in late 2022.Medscape Medical News (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - June 9, 2022 Category: Cardiology Tags: Diabetes & Endocrinology News Source Type: news
Testosterone therapy is associated with depression, suicidality, and intentional self-harm: analysis of a national federated database testosterone therapy with a man with equivocal testosterone levels - Corona G, Maggi M.
The relationship between mood disturbances and testosterone (T) levels is still conflicting and has not yet been completely clarified. Some observational studies have documented a weak association between male hypogonadism and the development of depressive... (Source: SafetyLit)
Source: SafetyLit - April 25, 2022 Category: International Medicine & Public Health Tags: Alcohol and Other Drugs Source Type: news
FDA Approves Tlando (testosterone undecanoate) for Male Hypogonadism
EWING, N.J., March 29, 2022 (GLOBE NEWSWIRE) -- Antares Pharma, Inc., (NASDAQ: ATRS) (the“Company”), a specialty pharmaceutical company, today announced that the U.S. Food and Drug Administration granted final approval for... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - March 29, 2022 Category: Drugs & Pharmacology Source Type: news
USA Swimming announces new policy for elite transgender athletes
The policy requires transgender women competing at elite levels to have low testosterone for 36 months — the longest of any sports governing body. #usaswimming #sportsgoverningbody (Source: Reuters: Health)
Source: Reuters: Health - February 2, 2022 Category: Consumer Health News Source Type: news
